source
- Lonza urges biotech firms to prioritize early de-risking to streamline IND pathIn a recent interview, Jaime Okray of Lonza highlighted that emerging biotech companies are shifting focus from pure speed to early identification of development risks as they aim for an IND filing…
- Agentic AI poised to reshape clinical development by moving beyond tools to autonomous decision-makingEarlier this year, a colleague argued that clinical leaders should stop asking whether they have an 'AI strategy', because the question often leads to the wrong conversation. Instead, leaders are…